New EPO Products Set To Boost Future Revenue For 3SBio
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30